Home » Authors » Cynthia Robbins-Roth

Articles by Cynthia Robbins-Roth

Filling The Pipeline: 'Early Stage' Firm Varies In Eyes Of Beholder

Nov. 20, 2006

By Cynthia Robbins-Roth

Filling The Pipeline: 'Early Stage' Firm Varies In Eyes Of Beholder

Nov. 20, 2006

By Cynthia Robbins-Roth

Smell Of Dollars Burning On Breeze Of Pre-Election

Nov. 6, 2006

By Cynthia Robbins-Roth

Smell Of Dollars Burning On Breeze Of Pre-Election

Nov. 6, 2006

By Cynthia Robbins-Roth

Considering Brain Disease, It's Time For New March Of Dimes

Oct. 23, 2006

By Cynthia Robbins-Roth

Considering Brain Disease, It's Time For New March Of Dimes

Oct. 23, 2006

By Cynthia Robbins-Roth

For Biotech CEOs, Does VC Grass Seem Greener?

Oct. 10, 2006

By Cynthia Robbins-Roth

For Biotech CEOs, Does VC Grass Seem Greener?

Oct. 10, 2006

By Cynthia Robbins-Roth

Fall Fun With Finances: School's Back In Session

Sep. 25, 2006

By Cynthia Robbins-Roth

Fall Fun With Finances: School's Back In Session

Sep. 25, 2006

By Cynthia Robbins-Roth

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 4, 2024.
In muscular dystrophies, gene therapies race the clock
BioWorld
Since the isolation of the gene that causes Duchenne muscular dystrophy (DMD), scientists have progressed in understanding the mechanisms that lead to muscular...
Bridgebio, with FDA approval, faces Pfizer in ATTR
BioWorld
With the U.S. FDA approval of Attruby (acoramidis) for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), Bridgebio Pharma Inc. is taking on an industry...
Phase III AMD miss leaves BLA Outlook same with bevacizumab
BioWorld
Outlook Therapeutics Inc. is forging onward with plans to resubmit the BLA for ONS-5010, an ophthalmic version of Avastin (bevacizumab, Roche AG), after a missed...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.